PMN Reports $0 Revenue, $0 EPS, Announces $175M Financing, PMN310 Phase 1b Enrolled 144 Patients, Fast Track Designation, No SAEs, Top-Line Data 2027
ProMIS Neurosciences Inc. Common Shares (ON) · PHARMACEUTICAL PREPARATIONS · Now $10.41
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS